Resources

Our community of economists and academic leaders from around the United States are united in their belief that more competition, innovation, accountability, consumer choice, and transparency are needed in America’s healthcare sector to improve the health and well-being of every patient.

Spending in the 340B Drug Pricing Program, 2010 to 2021

June 17, 2024

Congressional Budget Office

Presentation by Rebecca Sachs and Joshua Varcie, analysts in CBO’s Health Analysis Division, at the 13th Annual Conference of the American Society of Health Economists.

Federal Support Should Not Be A Factor In Determining Pharmaceutical Prices Under The IRA

June 14, 2024

Health Affairs

By Frederick McElwee, Amanda Cole, Louis P. Garrison, Jr., and Adrian Towse

Price Transparency in Health Care: The Consumer Opportunity

June 5, 2024

AEI Economic Perspectives

By James C. Capretta and Jack Rowing

Evaluating Pharmaceutical Policy Options

June 1, 2024

National Bureau of Economic Research

By Kate Ho and Ariel Pakes
NBER Working Paper No. 32606

The 340B Drug Discount Program Grew to $124B in 2023

May 10, 2024

IQVIA

By Rory Martin, PhD, and Harish Karne, MS